BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidance

What This Product Solves

BFH772 is a potent small-molecule VEGFR2 inhibitor specifically designed for precise modulation of VEGFR2-mediated signaling. It enables researchers to interrogate the VEGFR2 signaling pathway with high selectivity, making it an optimal choice for studies focused on angiogenesis inhibition and tumor angiogenesis research. The compound is engineered to minimize off-target interaction, exhibiting approximately 500-fold reduced potency against related receptors (FLK-1, FLT-1, FLT-4) and significantly lower efficacy against non-target kinases such as B-RAF, RET, and TIE-2, ensuring minimal confounding effects in pathway-specific assays (source: product_spec).

Researchers aiming to dissect VEGFR2-driven processes in models of tumor growth or pathological angiogenesis can use BFH772 as a selective tool to inhibit VEGFR2 activity without broadly suppressing other kinase-mediated pathways. This specificity distinguishes BFH772 from less selective angiogenesis inhibitors, reducing the risk of off-target effects in experimental systems.

Protocol Parameters

• In vitro kinase inhibition assay | IC₅₀ = 3 nM | Selective VEGFR2 signaling pathway inhibition | Enables high-affinity inhibition of VEGFR2, minimizing off-target kinase interaction | product_spec (product_spec)
• Compound solubility test | ≥53.4 mg/mL in DMSO, ≥15.33 mg/mL in ethanol | Required for preparation of concentrated stock solutions for cell-based studies | BFH772 is insoluble in water; organic solvents are necessary for dissolution | product_spec (product_spec)
• Storage condition | -20°C (dry, protected from light) | Maintains compound integrity for long-term use | Avoids degradation and preserves purity above 96% | product_spec (product_spec)
• Stock solution handling | Use immediately after preparation; avoid long-term storage | Ensures experimental reproducibility and compound stability | Solutions in DMSO or ethanol degrade over time; freshly prepared aliquots are recommended | workflow_recommendation

Workflow Setup and QC Checklist

To achieve consistent and reliable results with BFH772, adhere to the following workflow best practices:

• Solubility: Dissolve BFH772 only in DMSO or ethanol at concentrations up to 53.4 mg/mL and 15.33 mg/mL, respectively. Avoid water-based solvents, as the compound is insoluble in water (product_spec).
• Aliquoting and Storage: Prepare small aliquots of concentrated stock solution to minimize freeze-thaw cycles. Store all solid and solution forms at -20°C in a desiccated environment, protected from light.
• Fresh Solution Use: For optimal activity, use freshly prepared stock solutions. Long-term storage of solutions, even at low temperature, is not recommended due to potential degradation.
• Purity Check: Confirm receipt of certificate of analysis and purity data (purity >96%) before use. Reference the batch-specific QC to ensure validity of experimental results.
• Documentation: Maintain records of batch numbers and storage conditions for reproducibility.

For detailed protocol recommendations, see related internal articles such as this technical use guide, which outlines the importance of selectivity and solubility in experimental setup, and this QC guidance article for additional workflow optimization steps.

Common Failure Modes and Fixes

• Precipitation or incomplete dissolution: If BFH772 does not fully dissolve, verify use of anhydrous DMSO or ethanol at room temperature, and adjust solvent volume as needed. Avoid water and aqueous buffers at the stock preparation step.
• Loss of activity in stored solutions: If reduced activity is observed, prepare fresh stock from the solid compound. Discard any solution stored for extended periods, as compound stability is not assured in solution (product_spec).
• Unexpected cell toxicity: Confirm concentration calculations and ensure final DMSO or ethanol concentrations in working solutions are compatible with cell/tissue culture protocols. Titrate vehicle controls in parallel.
• Off-target effects: Given BFH772's selectivity, significant off-target kinase inhibition is unlikely, but always include appropriate negative and positive controls to rule out experimental artifacts.
• Batch-to-batch variability: Always verify purity and identity against the accompanying certificate of analysis and batch QC data before use.

Scope and Limitations

BFH772 is designed for targeted inhibition of VEGFR2 in research settings focused on angiogenesis and tumor model systems. Its high selectivity makes it well-suited for dissecting VEGFR2-specific pathways without broader kinase suppression. However, this specificity also means it is not appropriate for studies requiring non-selective angiogenesis inhibition or broad-spectrum kinase profiling.

The compound's solubility profile restricts its use to organic-solvent-based workflows; it is not suitable for water-based assays or protocols that demand water-soluble inhibitors. Researchers requiring aqueous solubility or broader kinase inhibition must select alternative agents. BFH772’s utility is best realized in controlled, pathway-specific studies where VEGFR2’s role is the primary focus.

For further details on experimental design and solubility considerations, refer to internal articles such as this technical protocols guide, which provides actionable steps for integrating BFH772 into angiogenesis research.

Conclusion

BFH772 (VEGFR2 inhibitor) is a powerful tool for researchers aiming to selectively interrogate VEGFR2-mediated angiogenesis, particularly in tumor growth models. Its stringent selectivity profile and defined solubility requirements demand careful workflow planning, from solvent choice to storage and QC documentation. By adhering to best practices and understanding the compound’s limitations, users can maximize the specificity and reproducibility of their VEGFR2 pathway studies. For full product specifications and supporting documentation, visit the BFH772 (VEGFR2 inhibitor) page on APExBIO.